The question of the AI bubble bursting is one of “when”, not “if” – and it’s a problem we can’t afford to ignore. The longer we do, the more expensive the correction will be.

The numbers are stark. Series B healthcare AI investment fell by 84% between the peak of Q4 2021 and Q4 2024. Startups that raised on the promise of transforming healthcare as we know it – compressing trial timelines, cutting the cost of failure, finding signals faster – are burning through their last rounds. The reality, in most cases, has been considerably more modest. Around 95% of enterprise AI pilots in healthcare have failed to deliver measurable ROI.

The tools that stall are not failing because AI does not work. They are failing because they were built for demonstration, not deployment – and because they met the messy, fragmented, interoperability-challenged reality of clinical data and had nowhere to go.

Meanwhile, tools such as ambient AI scribes are being deployed at scale with minimal validation and almost no regulatory oversight. A recent Health Affairs analysis described this as the “zombie algorithm” problem: AI embedded in clinical workflows that nobody has properly tested, that nobody fully understands, and that nobody is truly accountable for.

This is an argument for a different kind of AI. The kind I call “boring AI.”

Boring AI doesn’t get the headlines, but it does get the results

Boring AI isn’t glamorous; it doesn’t produce glossy dashboards or conversational interfaces. It’s so seamless you barely notice it's there. It operates quietly in the background, embedded deep within hospital EPR workflows, capturing structured, multimodal clinical data in real time at the point of care. This continuous multimodal data, spanning lab results, medication records, and clinical notes, forms a clinically governed dataset that few can match. By unifying this information across study sites and care settings, it surfaces actionable insights that enhance clinical decision-making. All without ostentatious technology or workflow disruption. For pharma, these data-based insights fuel faster, smarter decision-making.

Building for compliance is more than logging inputs. It means designing AI infrastructure to meet regulatory standards (class II AI Software as a Medical Device)that are validated, auditable, and explainable. Not retrofitted for regulation after the fact. Every input and output is recorded; every recommendation is traceable. The same rigour that makes the technology trusted at the bedside is what makes its underlying data uniquely valuable to pharma: real-time, point-of-care, longitudinal, and governed to clinical standards.

Co-designed with clinicians and sustained by a human-in-the-loop approach, it generates a regulatory-grade data asset that enables real-world evidence. The differentiation is not the AI itself; it’s the depth, quality, and credibility of the data that the AI infrastructure makes possible. This is particularly true in the case of Real‑world evidence (RWE).

The data problem pharma has been trying to solve for decades

Real World Evidence (RWE) has become one of pharma’s most strategic priorities. Yet despite billions spent, most RWE remains retrospective, manually coded, and disconnected from the reality of how patients are treated day to day. You cannot build reliable evidence on unreliable foundations.

This is where clinically embedded, validated data infrastructure changes the equation, not by creating new data flows, but by unlocking the structured, multimodal data already being generated inside hospitals. Because it operates within electronic patient record (EPR) workflows and captures longitudinal, real‑time information at the point of care, it produces a depth and fidelity of data that incumbent providers cannot match.

The differentiation is not the AI itself; it's the depth, quality, and credibility of the data that the AI infrastructure makes possible. This produces a continuously updated view of how patients actually present, deteriorate, respond, and recover, insight that underpins patient safety monitoring.

For pharma, this means trusted access to data that reflects real‑world clinical decision‑making, the treatment choices, adjustments, and escalations that no claims dataset can capture. Understanding those day‑to‑day realities is invaluable for R&D, market access, and evidence generation alike.

Regulated, traceable, hospital‑embedded data assets are what make reliable signal detection and meaningful RWE possible. The same rigour that makes this data credible at the bedside is what makes it uniquely valuable for life sciences partners.

The correction is coming. Build for what survives it

When the bubble bursts, the tools that survive will not be the ones that generated the best demos. They will be the ones embedded so deeply in clinical reality that removing them is unthinkable.

For pharma and biopharma executives navigating an increasingly crowded and sceptical AI landscape – whether evaluating acquisitions, structuring partnerships, or building internal capability – that is the question worth asking: is this tool built to last? Is it validated? Is it interoperable? Is it generating data you can actually use?

It turns out being boring has never been so beneficial.